- 询价
- Signalway Antibody
- USA
- CT603
- 2025年07月12日
- Mouse
企业认证
相关产品推荐更多 >
![PARD6A Antibody[35868]](https://img1.dxycdn.com/p/s14/2025/0922/359/6146153295428599691.jpg!wh200)
![N6AMT2 Polyclonal Antibody[30917]](https://img1.dxycdn.com/p/s14/2025/0923/305/2150219664296040791.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
A synthetic peptide NWSHPQFEK.
- 形态：
liquid
- 保存条件：
Store at 4˚C
- 克隆性：
单克隆
- 标记物：
AF350: 346nm/442nm <br/>AF405: 401nm/421nm <br/>AF488: 493nm/519nm <br/>AF555: 555nm/565nm <br/>AF594: 591nm/614nm <br/>AF647: 651nm/667nm <br/>AF680: 679nm/702nm <br/>AF750: 749nm/775nm <br/>Biotin
- 保质期：
6 months
- 库存：
详询
- 宿主：
Mouse
- 抗体英文名：
Strep II tag Mouse Conjugated Monoclonal Antibody
- 规格：
100ul
Suggested Dilution:
AF350 conjugated: most applications: 1: 50 - 1: 250
AF405 conjugated: most applications: 1: 50 - 1: 250
AF488 conjugated: most applications: 1: 50 - 1: 250
AF555 conjugated: most applications: 1: 50 - 1: 250
AF594 conjugated: most applications: 1: 50 - 1: 250
AF647 conjugated: most applications: 1: 50 - 1: 250
AF680 conjugated: most applications: 1: 50 - 1: 250
AF750 conjugated: most applications: 1: 50 - 1: 250
Biotin conjugated: working with enzyme-conjugated streptavidin，most applications: 1: 50 - 1: 1,000
specificity:
Strep a??-tag mouse monoclonal antibody detects endogenous levels of internal, C-terminal, and N-terminal Strep a?? tagged proteins.
formulation:
0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 10mg/ml Bovine Serum Albumin, 0.05% Sodium Azide
产品详细信息请点击：Strep II tag Mouse Conjugated Monoclonal Antibody
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Purification and Analysis of Strep-tagged Antibody-Fragments
The Strep-tag is a nine-residue minimal peptide sequence with intrinsic affinity towards streptavidin. This peptide – or its improved version Strep-tag II – can be fused to recombinant antibody fragments and other proteins in various fashions
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
The production of monoclonal antibody by hybridoma
The production of monoclonal antibody by hybridoma fusion: Immortalization of sensitized B lymphocytes from immune mice. Overview
技术资料暂无技术资料 索取技术资料
